Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Biosciences company, Bristol-Myers Squibb extend the term of research agreement
February 27th, 2006
Codexis, Inc., a privately held biosciences company, announced it has extended the term of an existing research agreement with Bristol-Myers Squibb Co. (BMY) (BMS). Codexis also announced that it will receive an undisclosed milestone payment for having successfully achieved the program's research milestone. The research agreement was announced May 24, 2005 and focused on improving biocatalyst productivity for an undisclosed product candidate in the Bristol-Myers Squibb pipeline using Codexis' proprietary MolecularBreeding directed-evolution platform. Under the extended term of the agreement Codexis will receive additional undisclosed research funding...
Source: Pharma Business Week (2006-02-27)
|
